These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Clinical evaluation of chemotherapy in urologic cancer].
    Author: Miki T, Kuroda M, Kotake T.
    Journal: Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1349-57. PubMed ID: 2471457.
    Abstract:
    In this paper, we will attempt to place the current status of the chemotherapy for testicular cancer, urothelial tumors and penile cancer in perspective. Perhaps the most exciting development in the past decade has been the demonstration of a significant number of complete responders (CR) to CDDP combined chemotherapy in patients with advanced testicular cancers. A CR rate of 60% was observed in the PVB therapy or VAB-6 therapy and no evidence of disease (NED) increased to 80% with salvage therapy. In our study of 43 evaluable patients, the CR rate was 60% and the NED rate was 81%. The activity of salvage chemotherapy with VP-16 for refractory testicular cancer has been well known with a CR rate of 19-38%. Among 13 evaluable patients with refractory cases, the CR rate was 46% with VP-16 or VM-26 salvage chemotherapy. The chemotherapeutic results of advanced urothelial cancers were also reviewed. In the present time, M-VAC therapy is thought to be the most effective regimen with a CR rate of 37%. In the chemotherapy of the primary lesion of penile cancer, bleomycin is most effective with a response rate of 60-70%. But for the primary lesion, there has been no effective chemotherapy.
    [Abstract] [Full Text] [Related] [New Search]